The funds will be used to conduct studies on Iantrek’s Micro-Interventional Glaucoma Surgical devices in the U.S.
Iantrek is the only glaucoma surgical company with FDA-registered technology to target outflow pathways.
“There remains a significant unmet clinical need to provide safe and effective micro-interventional tools for aqueous outflow management,” Sean Ianchulev, MD, Iantrek’s founder and CEO, said in an Aug. 30 press release. “We are grateful to have a world-class syndicate of investors supporting our efforts to advance these new technologies. With two commercial ready [Micro-Interventional Glaucoma Surgical] platforms, Iantrek is uniquely positioned to transform the horizon of micro-interventional ophthalmic surgery.”
